Defining the Interval between the Development of New Lesion on Follow Up Study and 1st Gamma Knife Radiosurgery without Whole-Brain Radiation Therapy in the Management of Brain Metastases by �옣醫낇씗 et al.
 
 
 
 
 
 39
KISEP ORIGINAL ARTICLE J of The Kor Soc of Ster and Func Neurosur 2007;3:39-43
 
Defining the Interval between the Development of New Lesion on  
Follow Up Study and 1st Gamma Knife Radiosurgery  
without Whole-Brain Radiation Therapy in the 
Management of Brain Metastases 
 
Young Keun Kim, MD, Jeong Han Kang, MD, Hyun Ho Jung, MD, 
Jong Hee Chang, MD, PhD, Jin Woo Chang, MD, PhD, Yong Gou Park, MD 
Department of Neurosurgery and Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea 
 
 
The aim of this retrospective study is to define the interval between the development of new lesion on follow up study and 1st 
gamma knife radiosurgery (GKS) without whole brain radiation therapy (WBRT) in the management of brain metastases. Between 
May 1992 and January 2006, 378 patients (207 males and 174 females) with brain metastases were treated with radiosurgery at the 
Yonsei University Medical Center. Reviewing the follow up study was available in 357 (81.7%) cases, and new lesions were found 
in 83 (23.2%) cases. We classified the development of new lesions after 1st GKS as missed, invisible, true new and undetermined 
lesions；missed lesions are those which were visible on MRI at the time of 1st GKS retrospectively, but omitted；invisible lesions, 
too small to be visualized on MRI at the time of 1st GKS, may be less than 1mm in size at that time and will be new lesions, visible 
on MRI within 4months after 1st GKS；true new lesions, newly metastasized to brain after GKS, developed 8 months after 1st GKS；
undetermined lesions, new lesions developed 5 to 7 months after 1st GKS. There were 12 patients (18.18%) of missed lesions, 
and the number of those lesions was 17；10 patients (15.15%) of invisible, and the number, 51；25 patients (37.88%) of unde-
termined, and the number, 166；19 patients (28.79%) of true new lesions, and the number, 100. The incidence of new lesion 
development was high between 5th and 7th months after GKS, and after that, it decreased suddenly. And that low incidence 
was even after 7th months. GKS without adjuvant WBRT showed good effect, however, strict MRI follow up at 4 and 7months after 
GKS is necessary to detect and treat the invisible and missed lesions. 
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INTRODUCTION 
 
In the last 15 years, radiosurgery (RS) as a therapeutic 
option was also considered for patients with brain meta-
stases who had controlled systemic disease and/or a good 
prognosis because of systemic therapies that are more ef-
fective.15) But after many studies have shown that RS is 
effective at controlling brain metastases and prolonging 
survival,9)10)14)17)18) radiosurgical treatment has gained in-
creasing therapeutic relevance for selected patients with 
small, circumscribed metastases in any location in the brain. 
However, many treatment issues still remain unresolved, 
such as the use of RS with or without whole-brain radio-
therapy (WBRT) and its value compared with other treat-
ment modalities. Especially RS has been used as a boost 
to WBRT or a primary modality followed by adjuvant 
WBRT with the mind that there may be distant micro-
metastases that would not be irradiated with radiosurgery 
alone.10) On the other hand, there are some reports about 
withholding WBRT until the time of further progression 
because of an increased risk of late complications from 
WBRT, such as radiation-induced dementia.6)11)25) 
The purpose of this study is to define the interval bet-
ween the development of new lesion on follow up study 
and 1st gamma knife radiosurgery (GKS) without WBRT 
in the management of brain metastases, so the additional 
treatment modalities can be chosen properly after that study. 
 
MATERIALS AND METHODS 
 
Patient population 
Between May 1992 and January 2006, 378 patients (207 
males and 174 females) with brain metastases were treated 
with radiosurgery at the Yonsei University Medical Center. 
The mean age was 61-year-old (range 24 to 90). Four 
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hundred and thirty seven procedures were done for 1760 
lesions. Among these procedures, GKS without WBRT 
were 364 procedures (83.3%) and GKS with WBRT, 73 
(16.7%). And 47 patients (12.4%) went repeated GKS 
treatment for the previous or new lesion found on follow 
up MRI. 
 
Treatment protocol and follow up evaluation 
The eligibility criteria for radiosurgical treatment were 
as followed：all patients had limited systemic disease and 
good Karnofsky Performance Scale (KPS) scores (more 
than 70). Also small (<3.5cm in maximum diameter) 
spherical, well-circumscribed lesions were included. Large 
size tumor (single or multiple) was surgically treated, and 
miliary or recurred multiple metastases was treated with 
WBRT. 
The median size of the lesions treated was 0.98cm3 
(range 0.02 to 22.6cm3). The median radiation dose at 
the isocenter was 27.21Gy (range 10 to 45Gy). The me-
dian radiation dose at the tumor margin was 16.31Gy 
(range 5 to 28.40Gy). And the median number of meta-
static lesions was 8 (range 1 to 29).  
MRI, with 1mm thin cut and double dose contrast 
enhancement, was used for follow up evaluation and was 
performed at every 3-month interval after 1st GKS. But 
when the patient had some new subjective symptoms, 
image scanning was done immediately. Reviewing the fol-
low up study was available in 357 (81.7%) cases, and new 
lesions were found in 83 (23.2%) cases. 
 
Classification of new lesions 
Reviewing follow up MRI, we classified the develop-
ment of new lesions after 1st GKS as missed, invisible, true 
new and undetermined lesions；missed lesions are those 
which were visible on MRI at the time of 1st GKS retro-
spectively, but omitted (Fig. 1)；invisible lesions, too 
small to be visualized on MRI at the time of 1st GKS, may 
be less than 1mm in size at that time and will be new le-
sions, visible on MRI within 4 months after 1st GKS 
(Fig. 2)；true new lesions, newly metastasized to brain 
after GKS, developed 8 months after 1st GKS (Fig. 3)；
undetermined lesions, new lesions developed 5 to 7 months 
after 1st GKS. 
 
RESULTS 
 
Incidence of new lesion development after 1st GKS without 
WBRT 
There were 12 patients (18.18%) of missed lesions, and 
Fig. 1. Axial T1-weighted MR images with Gadolinium enhance-
ment. Upper：At the time of 1st GKS image shows a metastatic
mass less than 1cm in diameter on right occipital lobe (white ar-
row). Lower：Follow up image of 6 months after GKS showed
reduction of previous treated lesion, but multiple new lesions were
emerged (black arrow). Previous image was re-examed, and
these lesions were visible, but we missed (black arrow on upper).
Fig. 2. Axial T1-weighted MR images with Gadolinium enhance-
ment. Upper：At the time of 1st GKS images shows a metastatic 
lesion with peritumoral edema on right parietal lesion. Lower：Fol-
low up image of 3 months after GKS showed reduction of pre-
vious treated lesion and peritumoral edema, but multiple new le-
sions were emerged (black arrow). May be they were too small 
to be visualized on MRI at the time of GKS, so we called invisible 
lesion. 
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the number of those lesions was 17；10 patients (15.15%) 
of invisible, and the number, 51；25 patients (37.88%) of 
undetermined, and the number, 166；19 patients (28.79%) 
of true new lesions, and the number, 100. The incidence of 
new lesion development after 1st GKS without WBRT is 
summarized in Table 1. 
 
Timing of the development of new lesions after 1st GKS with-
out WBRT 
The incidence of new lesion development was high bet-
ween 5th and 7th months after GKS, and after that, it de-
creased suddenly. And that low incidence was even after 
7th months (Fig. 4). 
 
DISCUSSION 
 
Multiple treatments, such as surgery, RS, WBRT, che-
motherapy, immunotherapy and others, etc., are now avai-
lable for patients with brain metastases. And many studies 
have shown that RS is effective at controlling brain me-
tastases and prolonging survival.9)10)14)17)18) Also results of 
well-designed studies for the treatment of single metastases 
have demonstrated that, for patients with a reasonable 
prognosis, RS plus WBRT is superior to WBRT alone.1) 
But RS plus WBRT (RS as a adjuvant therapy after 
WBRT) didn’t show the improved survival in the mana-
gement of single and multiple metastases.3)4)7)24) Sneed 
et al. reported that survival and local tumor control were 
Table 1. Classification of new lesions 
Type No. of lesions No. of patients (%)
Missed 017 12 (018.18%) 
Invisible (<4m.) 051 10 (015.15%) 
Undetermined (5-7m.) 166 25 (037.88%) 
True (>8m.) 100 19 (028.79%) 
Total 324 66 (100%)00. 
No.：numbers, m.：months 
 
Fig. 3. Axial T1-weighted MR images with Gadolinium enhancement. Left：At the time of 1st GKS images shows a metastatic lesion on 
right cerebellum (black arrow). Middle：Follow up image of 10months after GKS showed well controlled previous lesion without new
lesion development. Right：Follow up image of 25months after GKS showed multiple lesions (white arrow) on cerebellum, which sites were
not previously treated ones and we called these, true new lesions. 
Fig. 4. The incidence of new lesion de-
velopment was high between 5th and
7th months after GKS, and after that, it
decreased suddenly. And that low in-
cidence was even after 7th months.
These findings suggest that the number
of undetermined lesions must be the
sum of the number of invisible lesions
and true new lesions developed during
that period. 
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almost the same for radiosurgery alone versus stereotactic 
RS and WBRT.5)7)18)23)24)29) It was same results in our data 
that WBRT was not a significant variable on the local tu-
mor control (p=0.6555, not shown in this study). 
Even though WBRT may control micrometastases not 
seen on MRI, there are some group withholding WBRT 
for the purpose of avoiding short-term toxicity and long-
term cognitive problems in patients with limited brain 
disease.2)5)8)10)12)13)17-24)26-28) Especially the late toxicities, 
such as memory impairment, personality change and neu-
rocognitive deficits, which occur more than 90 days after 
treatment, is problematic for the long term surviving pa-
tients in the point of quality of life.1)6)16) 
Another reason for withholding WBRT is that it makes 
difficulty in selecting the appropriate dosage. The single 
dose equivalent (SDE) of fractionated WBRT is variable 
according to formula, and the total SDE (sum of WBRT 
and RS) is not clearly known. And when it is combined 
with WBRT, the fall-off curve of RS will be flattened. For 
example, when SDE of fractionated WBRT is 10Gy, 5Gy 
of RS (margin dose in 50% isodose) will be not enough 
maximum dose for the control of tumor, because total SDE 
of margin dose will be 15Gy and maximum 20Gy. On the 
other hand, 10Gy of RS will be too much for the margin 
dose, total SDE of margin dose will be 20Gy and maxi-
mum 30Gy, and it could raise the risk of radiation toxicity. 
Hasegawa et al. suggested that periodic imaging exa-
minations, every 3 to 4 months during the first 2 years, are 
required after RS for brain metastases.10) But there was no 
report suggesting follow up period with objective data in 
the treatment of brain metastases with RS only. This is our 
purpose of study to define the interval between the deve-
lopment of new lesion on follow up study and 1st GKS 
without WBRT. In our results, the incidence of new lesion 
development was high between 5th and 7th months after 
GKS, and after that, it decreased suddenly. And that low 
incidence was even after 7th months. These findings sug-
gest that the number of undetermined lesions must be the 
sum of the number of invisible lesions and true new le-
sions developed during that period. So the additional treat-
ment must be added for these lesions at that time, WBRT 
or RS whatever will be. 
 
CONCLUSION 
 
The incidence of new lesion development was high bet-
ween 5th and 7th months after GKS, and after that, it de-
creased suddenly. And that low incidence was even after 
7th months. GKS without adjuvant WBRT showed good 
effect on tumor control, however, strict MRI follow up at 
5th and 7th months after GKS is necessary to detect and 
treat the invisible and missed lesions. 
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